Related Experiment Video

Updated: Oct 24, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.2K

Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives

Adriana A Garcia1, Ana Koperniku1, Julio C B Ferreira2

  • 1Department of Chemical and Systems Biology, School of Medicine, Stanford University, Stanford, CA, USA.

Trends in Pharmacological Sciences
|August 14, 2021
PubMed

Insights

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects millions globally, causing hemolytic anemia. Current treatments are lacking, but new therapeutic targets in metabolic pathways offer hope for developing effective G6PD deficiency drugs.

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) is crucial for cellular redox balance and red blood cell protection against oxidative stress.
  • G6PD deficiency, a genetic disorder affecting approximately 400 million people worldwide, can lead to acute hemolytic anemia.
  • No specific therapeutics currently exist for G6PD deficiency, necessitating research into treatment strategies.

Purpose of the Study:

  • To review the role of G6PD in various disorders.
  • To analyze past treatment strategies and their limitations for G6PD deficiency.
  • To identify and discuss potential pharmacological targets for therapeutic development.

Main Methods:

  • Literature review of G6PD's role in hemolytic and nonhemolytic disorders.
  • Analysis of historical treatment approaches for G6PD deficiency.
  • Exploration of potential therapeutic pathways including glutathione metabolism and NADPH production.

Main Results:

  • G6PD deficiency is linked to significant health issues, primarily hemolytic anemia.
  • Previous treatment attempts have had limited success, highlighting the need for novel approaches.
  • Several potential drug targets have been identified, including those related to GSH metabolism and gene regulation.

Conclusions:

  • There is a critical unmet need for effective therapeutics for G6PD deficiency.
  • Targeting specific metabolic pathways and gene regulation presents promising avenues for drug development.
  • Further research into these targets could lead to treatments for G6PD deficiency and associated chronic diseases.

Keywords:
G6PD deficiencyN-acetyl-cysteineenzyme activatorstherapeutic strategytranscriptional regulators

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

8.3K
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.6K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
589
Other Glycolytic Pathways01:24

Other Glycolytic Pathways

The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...
351
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.2K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
474
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
366
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K